These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31131592)

  • 1. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
    Ruiz Ramos J; Salavert Lletí M
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):45-54. PubMed ID: 31131592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon.
    Ballouz T; Zeenny RM; Haddad N; Rizk N; Kanj SS
    J Infect Dev Ctries; 2021 Sep; 15(9):1308-1313. PubMed ID: 34669601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.
    Karageorgopoulos DE; Wang R; Yu XH; Falagas ME
    J Antimicrob Chemother; 2012 Feb; 67(2):255-68. PubMed ID: 22096042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes.
    Kaye KS; Gales AC; Dubourg G
    Int J Antimicrob Agents; 2017 May; 49(5):542-548. PubMed ID: 28130072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria.
    Wangchinda W; Rattanaumpawan P
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35951643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections.
    Saiprasad PV; Krishnaprasad K
    Indian J Med Microbiol; 2016; 34(4):416-420. PubMed ID: 27934817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
    Meschiari M; Faltoni M; Kaleci S; Tassoni G; Orlando G; Franceschini E; Burastero G; Bedini A; Serio L; Biagioni E; Melegari G; Venturelli C; Sarti M; Bertellini E; Girardis M; Mussini C
    Int J Antimicrob Agents; 2024 May; 63(5):107134. PubMed ID: 38453094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Rates of Fosfomycin Resistance in Gram-Negative Urinary Isolates from Israel.
    Peretz A; Naamneh B; Tkhawkho L; Nitzan O
    Microb Drug Resist; 2019 Apr; 25(3):408-412. PubMed ID: 30724694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
    Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
    Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.